HSP70 vaccine in combination with gene therapy with plasmid DNA encoding sPD-1 overcomes immune resistance and suppresses the progression of pulmonary metastatic melanoma

International Journal of Cancer

Volumn 118, Issue 11, 2006, Pages 2657-2664

  Geng, Hui ^a   Zhang, Gui Mei ^a   Xiao, Han ^a   Yuan, Ye ^a   Li, Pong ^a   Zhang, Hui ^a   Qiu, Hui ^a   He, Yu Fei ^a   Feng, Zuo Hua ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Gene therapy; Immune escape; Tumor immunity; Tumor immunotherapy

Indexed keywords

CELL SURFACE PROTEIN; CYTOKINE; GAMMA INTERFERON; HEAT SHOCK PROTEIN 70; INTERLEUKIN 2; PLASMID DNA; PROTEIN B7 H1; PROTEIN SPD 1; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; FEMALE; GENE THERAPY; IMMUNITY; LUNG METASTASIS; LYMPHOCYTIC INFILTRATION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TH1 CELL; TUMOR IMMUNITY; TUMOR RESISTANCE;

ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; CANCER VACCINES; FEMALE; GENE THERAPY; HSP70 HEAT-SHOCK PROTEINS; IMMUNOTHERAPY; INTERFERON TYPE II; INTERLEUKIN-2; LUNG NEOPLASMS; MELANOMA; MICE; MICE, INBRED C57BL; SKIN NEOPLASMS; T-LYMPHOCYTES; UP-REGULATION;

EID: 33646345848     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21795     Document Type: Article

References (46)

1. Udono H, Srivastava PK. Heat shock protein 70-associated peptides elicit specific cancer immunity. J Exp Med 1993;178:1391-96.
2. Liu B, DeFilippo AM, Li Z. Overcoming immune tolerance to cancer by heat shock protein vaccines. Mol Cancer Ther 2002;1:1147-51.
3. Srivastava PK. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 2002;20:395-425.
4. Ciupitu AM, Petersson M, O'Donnell CL, Williams K, Jindal S, Kiessling R, Welsh RM. Immunization with a lymphocytic choriomeningitis virus peptide mixed with heat shock protein 70 results in protective antiviral immunity and specific cytotoxic T lymphocytes. J Exp Med 1998;187:685-91.
5. Arnold DS, Faath S, Rammensee H, Schild H. Cross-priming of minor histocompatibility antigenspecific cytotoxic T cells upon immunization with the heat shock protein gp96. J Exp Med 1995;182:885-9.
6. Castellino F, Boucher PE, Eichelberg K, Mayhew M, Rothman JE, Houghton AN, Germain RN. Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways. J Exp Med 2000;191:1957-64.
7. Basu S, Binder RJ, Ramalingam T, Srivastava PK. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 2001;14:303-313.
8. Asea A, Rehli M, Kabingu E, Boch JA, Bare O, Auron PE, Stevenson MA, Calderwood SK. Novel signal transduction pathway utilized by extracellular Hsp70: role of toll-like receptor (TLR) 2 and TLR4. J Biol Chem 2002;277:15028-34.
9. Binder RJ, Han DK, Srivastava PK. CD91: a receptor for heat shock protein gp96. Nat Immunol 2000;1:151-5.
10. Asea A, Kraeft SK, Kurt-Jones EA, Stevenson MA, Chen LB, Finberg RW, Koo GC, Calderwood SK. Hsp70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med 2000;6:435-42.
11. Kojima T, Yamazaki K, Tamura Y, Ogura S, Tani K, Konishi J, Shinagawa N, Kinoshita I, Hizawa N, Yamaguchi E, Dosaka-Akita H, Nishimura M. Granulocyte-macrophage colonystimulating factor gene-transduced tumor cells combined with tumor-derived gp96 inhibit tumor growth in mice. Hum Gene Ther 2003;14:715-28.
12. Tamura Y, Peng P, Liu K, Daou M, Srivastava PK. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 1997;278:117-20.
13. Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD, Roederer M, Davis MM. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999;5:677-85.
14. Dunbar PR, Smith CL, Chao D, Salio M, Shepherd D, Mirza F, Lipp M, Lanzavecchia A, Sallusto F, Evans A, Russell-Jones R, Harris AL, et al. A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response. J Immunol 2000;165:6644-52.
15. Romero P, Dunbar PR, Valmori D, Pittet M, Ogg GS, Rimoldi D, Chen JL, Lienard D, Cerottini JC, Cerundolo V. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 1998;188:1641-50.
16. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8.
17. Ravetch JV, Lanier LL. Immune inhibitory receptors. Science 2000;290:84-9.
18. Dong HD, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Cells E, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793-800.
19. Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, Krzysike R, Knutson KL, Daniel B, Zimmermann MC, David O, Burow M, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003;9:562-7.
20. Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999;5:1365-9.
21. Strome SE, Dong HD, Tamura HH, Voss SG, Flies DB, Tamada K, Salomao D, Cheville J, Hirano F, Lin W, Kasperbauer JL, Ballman KV, et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res 2003;63:6501-5.
22. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of B7-H1 on tumor cells in the escape from host immune system and tumor immunotherapy by B7-H1 blockade. Proc Natl Acad Sci USA 2002;199:12293-7.
23. + T cells. Cancer Res 2004;64:1140-5.
24. Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, Rietz C, Flies DB, Lau JS, Zhu G, Tamada K, Chen L. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005;65:1089-96.
25. He YF, Zhang GM, Wang XH, Zhang H, Yuan Y, Li D, Feng ZH. Blocking programmed death (PD)-Ligand-PD-1 interactions by local gene therapy results in enhancement of antitumor effect of secondary lymphoid tissue chemokine. J Immunol 2004;173:4919-28.
26. Feng ZH, Huang B, Zhang GM, Li D, Wang HT. Investigation on the effect of peptides mixture from tumor cells inducing anti-tumor specific immune response. Sci China C Life Sci 2002;45:361-9.
27. Moroi Y, Mayhew M, Trcka J, Hoe MH, Takechi Y, Ulrich Hartl F, Rothman JE, Houghton AN. Induction of cellular immunity by immunization with novel hybrid peptides complexed to heat shock protein 70. Proc Natl Acad Sci USA 2000;97:3485-90.
28. Blachere NE, Li ZH, Chandauarkar RY, Suto R, Jaikaria NS, Basu S, Udono H, Srivastava PK. Heat shock protein-peptide complexes reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J Exp Med 1997;186:1315-22.
29. Wang G, Tschoi M, Spolski R, Lou YY, Ozaki K, Feng CG, Kim G, Leonard WJ, Hwu P. In Vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res 2003;63:9016-22.
30. Herweijer H, Wolff JA. Progress and prospects: naked DNA gene transfer and therapy. Gene Ther 2003;10:453-8.
31. Zhang G, Gao X, Song YK, Vollmer R, Stolz DB, Gasiorowski JZ, Dean DA, Liu D. Hydroporation as the mechanism of hydrodynamic delivery. Gene Ther 2004;11:675-82.
32. Jeannin P, Magistrelli G, Aubry JP, Caron G, Gauchat JF, Renno T, Herbault N, Goetsch L, Blaecke A, Dietrich PY, Bonnefoy JY, Delneste Y. Soluble CD86 is a costimulatory molecule for human T lymphocytes. Immunity 2000;13:303-12.
33. Sun X, Vale M, Leung E, Kanwar JR, Gupta R, Krissansen GW. Mouse. B7-H3 induces antitumor immunity. Gene Ther 2003;10:1728-34.
34. + T Cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001;61:4766-72.
35. Blohm U, Roth E, Brommer K, Dumrese T, Rosenthal FM, Pircher H. Lack of effector cell function and altered tetramer binding of tumor-infiltrating lymphocytes. J Immunol 2002;169:5522-30.
36. Dobrzanski MJ, Reome JB, Hollenbaugh JA, Dutton RW. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 anti-tumor responses. J Immunol 2004;172:1380-90.
37. Kammula US, Lee KH, Riker AI, Wang E, Ohnmacht GA, Rosenberg SA, Marincola FM. Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. J Immunol 1999;163:6867-75.
38. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15.
39. Curier TJ, Coukos G, Zou LH, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters privilege and predicts reduced survival. Nat Med 2004;10:942-9.
40. He YF, Wang XH, Zhang GM, Chen HT, Zhang H, Feng ZH. Sustained low-level expression of interferon-γ promotes tumor development: potential insights in tumor prevention and tumor immunotherapy. Cancer Immunol Immunother 2005;54:891-7.
41. Iwai Y, Terawaki S, Ikegawa M, Okazaki T, Honjo T. PD-1 inhibits antiviral immunity at the effector phase in the liver. J Exp Med 2003;198:39-50.
42. + T cells. Immunity 2005;22:371-83.
43. Mocellin S, Wang E, Marincola FM. Cytokines and immune response in the tumor microenvironment. J Immunother 2001;24:392-407.
44. Coughlin CM, Salhany KE, Gee MS, LaTemple DC, Kotenko S, Ma X, Gri G, Wysocka M, Kim JE, Liu L, Liao F, Farber JM, et al. Tumor cell responses to IFN-γ affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 1998;9:25-34.
45. Cheng JH, Zhou T, Liu CD, Shapiro JP, Brauer MJ, Kiefer MC, Bar PJ, Mountz JD. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994;263:1759-62.
46. Oaks MK, Hallett KM. Cutting edge: a soluble form of CTLA-4 in patients with autoimmune thyroid disease. J Immunol 2000;164:5015-18.